Table of Contents
Chapter 1. Global Growth Hormone Deficiency Market Executive Summary
1.1. Global Growth Hormone Deficiency Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Treatment Type
1.3.2. By Disease Indication
1.3.3. By Route of Administration
1.3.4. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Growth Hormone Deficiency Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Growth Hormone Deficiency Market Dynamics
3.1. Market Drivers
3.1.1. Rise in Incidence of Growth Hormone Deficiencies
3.1.2. Increase in Geriatric Population
3.2. Market Challenges
3.2.1. Lack of Skilled Professionals
3.2.2. Complexity of Treatment Regimens
3.3. Market Opportunities
3.3.1. Growing Awareness about Hormonal Deficiencies
3.3.2. Advancements in Treatment Methodologies
3.3.3. Increasing Healthcare Investments in Emerging Markets
Chapter 4. Global Growth Hormone Deficiency Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Growth Hormone Deficiency Market Size & Forecasts by Treatment Type 2022-2032
5.1. Segment Dashboard
5.2. Global Growth Hormone Deficiency Market: Treatment Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Therapeutic Treatment
5.2.2. Recombinant Human Growth Hormone
5.2.3. Human Pituitary Gland Extracts
5.2.4. Surgery
Chapter 6. Global Growth Hormone Deficiency Market Size & Forecasts by Disease Indication 2022-2032
6.1. Segment Dashboard
6.2. Global Growth Hormone Deficiency Market: Disease Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Pediatric Growth Hormone Deficiency
6.2.2. Idiopathic Short Stature
6.2.3. Small for Gestational Age
6.2.4. Turner Syndrome
6.2.5. Adult Growth Hormone Deficiency
6.2.6. Others (Prader-Willi Syndrome, etc.)
Chapter 7. Global Growth Hormone Deficiency Market Size & Forecasts by Route of Administration 2022-2032
7.1. Segment Dashboard
7.2. Global Growth Hormone Deficiency Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Subcutaneous
7.2.2. Intramuscular
7.2.3. Intravenous
Chapter 8. Global Growth Hormone Deficiency Market Size & Forecasts by Distribution Channel 2022-2032
8.1. Segment Dashboard
8.2. Global Growth Hormone Deficiency Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
Chapter 9. Global Growth Hormone Deficiency Market Size & Forecasts by Region 2022-2032
9.1. North America Growth Hormone Deficiency Market
9.1.1. U.S. Growth Hormone Deficiency Market
9.1.1.1. Treatment Type breakdown size & forecasts, 2022-2032
9.1.1.2. Disease Indication breakdown size & forecasts, 2022-2032
9.1.1.3. Route of Administration breakdown size & forecasts, 2022-2032
9.1.1.4. Distribution Channel breakdown size & forecasts, 2022-2032
9.1.2. Canada Growth Hormone Deficiency Market
9.2. Europe Growth Hormone Deficiency Market
9.2.1. U.K. Growth Hormone Deficiency Market
9.2.2. Germany Growth Hormone Deficiency Market
9.2.3. France Growth Hormone Deficiency Market
9.2.4. Spain Growth Hormone Deficiency Market
9.2.5. Italy Growth Hormone Deficiency Market
9.2.6. Rest of Europe Growth Hormone Deficiency Market
9.3. Asia-Pacific Growth Hormone Deficiency Market
9.3.1. China Growth Hormone Deficiency Market
9.3.2. India Growth Hormone Deficiency Market
9.3.3. Japan Growth Hormone Deficiency Market
9.3.4. Australia Growth Hormone Deficiency Market
9.3.5. South Korea Growth Hormone Deficiency Market
9.3.6. Rest of Asia Pacific Growth Hormone Deficiency Market
9.4. Latin America Growth Hormone Deficiency Market
9.4.1. Brazil Growth Hormone Deficiency Market
9.4.2. Mexico Growth Hormone Deficiency Market
9.4.3. Rest of Latin America Growth Hormone Deficiency Market
9.5. Middle East & Africa Growth Hormone Deficiency Market
9.5.1. Saudi Arabia Growth Hormone Deficiency Market
9.5.2. South Africa Growth Hormone Deficiency Market
9.5.3. Rest of Middle East & Africa Growth Hormone Deficiency Market
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Novo Nordisk A/S
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Pfizer Inc.
10.3.3. Merck KGaA
10.3.4. Eli Lilly and Company
10.3.5. Novartis AG
10.3.6. F. Hoffmann-La Roche AG
10.3.7. Ipsen Pharma
10.3.8. Ferring Pharmaceuticals
10.3.9. Anhui Anke Biotechnology (Group) Co., Ltd.
10.3.10. Zhongshan Sinobioway Hygene Biomedicine Co., Ltd.
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes